A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
about
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancerOnce versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolismAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerOnce versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolismVenous thromboembolic diseaseAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesLow-molecular-weight heparins in the treatment of venous thromboembolismMeasuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewEligibility for home treatment of deep vein thrombosis: prospective studyImpact of thromboprophylaxis across the US acute care settingElevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity.Danaparoid sodium.Management of venous thromboembolism during pregnancy.Safety of low molecular weight heparins in the treatment of venous thromboembolism.Unfractionated heparin: focus on a high-alert drug.Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.Latest medical treatment strategies for venous thromboembolism.Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide.Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry.The Treatment of Venous Thromboembolism in Patients with Cancer.Impact of venous thromboembolism and anticoagulation on cancer and cancer survivalPerioperative anticoagulation in patients with mechanical heart valves undergoing elective surgery: results of a survey conducted among Korean physicians.Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.Indirect comparisons: a review of reporting and methodological qualityCost-Effectiveness Analysis of the Unfractionated Heparin versus Low-Molecular-Weight Heparin in Hospitalized Patients with Stroke Due to Atrial Fibrillation in Shiraz, South of Iran.Anticoagulation for venous thromboembolism. What are the current options?Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.Differentiation of the low-molecular-weight heparins.Dalteparin sodium.Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.Once versus twice daily LMWH for the initial treatment of venous thromboembolism.Low-molecular-weight heparins: are they all the same?Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.Hypercoagulable state testing and malignancy screening following venous thromboembolic events.From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer.Low molecular weight heparin: a practical approach in deep venous thrombosis in palliative careBritish Thoracic Society guidelines for the management of suspected acute pulmonary embolism
P2860
Q24193871-BC198F6A-D40F-4CBA-87E4-50A7B1094F46Q24201186-448587D3-0897-49ED-9D4A-A5AFEA2FE3FFQ24234155-89BC4FD1-2A78-4E9F-ADC3-3C77CD4A8A1DQ24235193-18036683-E907-4E19-9813-2EF8ACAAC57BQ24236443-A7A7EA1B-31DF-4DB7-9C63-CC78EF3B839FQ24242243-2CE53C89-CBBD-49C4-ACAD-4444287AA99DQ24246284-3D715767-3AEB-41E1-B6D7-744FFDC86789Q24631121-72D0DD99-0189-4C71-9E66-75F431B75A21Q24633053-F2FAA8C8-0929-499A-973D-1EAF5C62A992Q24792692-27FC169B-D2C6-4982-96E7-1E656DAC4DD5Q26992262-9454213D-66A2-442A-A08E-8C3CDB4F1E08Q28365313-E0BBA8EE-0811-496D-B28C-F0910793952EQ28651190-7002018F-0164-48BC-AAFE-F87CE0B83E09Q31975827-AFC4930C-F04A-4C93-83F3-D07753DC3F93Q33336359-26E9E8EC-3A42-4652-AD2B-91B8684B3890Q33349065-76F6763D-5CF5-4E1E-ACA7-4EFFA9A2509BQ33349368-B9543CA2-CF2B-43D9-9256-08A834B5C615Q33362322-839F1EA0-ADA1-4276-A1FC-FD30C2507157Q33372266-5DCE06DD-5F11-4872-B3C3-4627BBBF10C5Q33375535-EFC5F812-EEB0-4138-8764-0FFF44906527Q33385947-B2EE5D75-BFA6-41EA-BA02-1C4338389880Q33395797-DA4EF67F-0AE9-4B8D-8054-3B93272C57D8Q33435329-6042009B-7586-433B-909F-ECE6B1AACA13Q33561203-5D81162D-DEAB-434D-A79A-D565353307E1Q33659307-842E2861-5BAD-4CD4-8EBD-79965BEC94ACQ33685447-CEEDFC3D-5140-4DEE-B543-35B6FFF0FA20Q33750311-68647466-1630-4F0B-B724-CF02C0A8FBF3Q33882994-58A7624E-9F15-4EEB-8089-39AD605DA18CQ34054473-881AF6A1-1F35-44FA-AEE1-1C6B50748A6EQ34278853-C5946C68-6126-4942-83AA-2D74FA483EB2Q34278856-649D501D-FFD0-4317-B681-90DCBEA8CE05Q34390254-DC7FC428-732F-4EB6-8695-FB316AF2C98AQ34688195-AE24ADF1-215C-4779-9B07-83F332FEE770Q35048657-74892C01-1733-49EA-94D9-B77FCC619666Q35096649-A699A44D-0E8B-48FF-BC7E-3F58F7A7F726Q35174604-9BD60052-7029-4493-BF58-68793E4E4B7FQ35179215-C3EE5CAA-F892-433E-A662-D08F6B4C9D11Q35181616-B9FCDFA9-04EB-46CD-9855-AA9DEBA2FE52Q35245073-2A2792D2-47E3-48B6-98E7-97037A8131AEQ35535961-E514C2F4-CC8B-4DB4-8A56-DCD8AC812582
P2860
A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
A meta-analysis comparing low- ...... ct type, and dosing frequency.
@ast
A meta-analysis comparing low- ...... ct type, and dosing frequency.
@en
A meta-analysis comparing low- ...... ct type, and dosing frequency.
@nl
type
label
A meta-analysis comparing low- ...... ct type, and dosing frequency.
@ast
A meta-analysis comparing low- ...... ct type, and dosing frequency.
@en
A meta-analysis comparing low- ...... ct type, and dosing frequency.
@nl
prefLabel
A meta-analysis comparing low- ...... ct type, and dosing frequency.
@ast
A meta-analysis comparing low- ...... ct type, and dosing frequency.
@en
A meta-analysis comparing low- ...... ct type, and dosing frequency.
@nl
P2093
P1476
A meta-analysis comparing low- ...... ct type, and dosing frequency.
@en
P2093
Dolovich LR
Douketis JD
Ginsberg JS
Holbrook AM
P304
P356
10.1001/ARCHINTE.160.2.181
P407
P577
2000-01-01T00:00:00Z